Omadacycline hydrochloride is a tetracycline-class antibiotic used to treat various bacterial infections. It is FDA-approved for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). The drug inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, offering a valuable option for intravenous or oral therapy. Its broad-spectrum activity targets both Gram-positive and Gram-negative bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). It is particularly beneficial for patients with allergies to other antibiotics, resistance issues, or when prior treatments fail due to side effects or contraindications. No dose adjustment is required in patients with renal impairment, making it suitable for those with kidney dysfunction. As a pharmaceutical intermediate, it is also utilized in research, drug development, and manufacturing of antibiotic formulations. Administration occurs in hospital or outpatient settings based on infection severity and patient condition.